JP2010503682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010503682A5 JP2010503682A5 JP2009528319A JP2009528319A JP2010503682A5 JP 2010503682 A5 JP2010503682 A5 JP 2010503682A5 JP 2009528319 A JP2009528319 A JP 2009528319A JP 2009528319 A JP2009528319 A JP 2009528319A JP 2010503682 A5 JP2010503682 A5 JP 2010503682A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- pharmaceutical composition
- compound according
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 108091005502 Aspartic proteases Proteins 0.000 claims 13
- 102000035101 Aspartic proteases Human genes 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 7
- 239000005541 ACE inhibitor Substances 0.000 claims 5
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 5
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 5
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 5
- -1 methyl compound Chemical class 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000009977 dual effect Effects 0.000 claims 4
- 229940044551 receptor antagonist Drugs 0.000 claims 4
- 239000002464 receptor antagonist Substances 0.000 claims 4
- 208000019553 vascular disease Diseases 0.000 claims 4
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 3
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 3
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 239000002160 alpha blocker Substances 0.000 claims 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 3
- 239000002876 beta blocker Substances 0.000 claims 3
- 229940097320 beta blocking agent Drugs 0.000 claims 3
- 239000000480 calcium channel blocker Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000002934 diuretic Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- KNTZCGBYFGEMFR-UHFFFAOYSA-N (propan-2-ylazaniumyl)formate Chemical compound CC(C)NC(O)=O KNTZCGBYFGEMFR-UHFFFAOYSA-N 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- FZBZOIXHKQUVBU-KGLIPLIRSA-N 2-trimethylsilylethyl n-[(2s)-2-amino-3-[(3r)-oxan-3-yl]propyl]-n-methylcarbamate Chemical compound C[Si](C)(C)CCOC(=O)N(C)C[C@@H](N)C[C@H]1CCCOC1 FZBZOIXHKQUVBU-KGLIPLIRSA-N 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 229940097420 Diuretic Drugs 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 108010010369 HIV Protease Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 206010062886 Procedural hypertension Diseases 0.000 claims 2
- 108090000783 Renin Proteins 0.000 claims 2
- 102100028255 Renin Human genes 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- 230000004410 intraocular pressure Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 claims 2
- 108010020708 plasmepsin Proteins 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 150000003892 tartrate salts Chemical class 0.000 claims 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 1
- 125000006242 amine protecting group Chemical group 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001452 natriuretic effect Effects 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- FBAOEVPHUAUGSW-MIEMQEKWSA-N CNC[C@H](CC1COCCC1)NC(N(CCC1)C[C@@H]1[C@H](c1cc(Cl)cc(F)c1)OCCNC(OC)=O)=O Chemical compound CNC[C@H](CC1COCCC1)NC(N(CCC1)C[C@@H]1[C@H](c1cc(Cl)cc(F)c1)OCCNC(OC)=O)=O FBAOEVPHUAUGSW-MIEMQEKWSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84533106P | 2006-09-18 | 2006-09-18 | |
| PCT/US2007/020086 WO2008036216A1 (en) | 2006-09-18 | 2007-09-17 | Piperidine derivatives as renin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010503682A JP2010503682A (ja) | 2010-02-04 |
| JP2010503682A5 true JP2010503682A5 (enExample) | 2010-11-11 |
Family
ID=38926325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009528319A Withdrawn JP2010503682A (ja) | 2006-09-18 | 2007-09-17 | レニン阻害剤としてのピペリジン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090318501A1 (enExample) |
| EP (1) | EP2081927B1 (enExample) |
| JP (1) | JP2010503682A (enExample) |
| AT (1) | ATE520690T1 (enExample) |
| WO (1) | WO2008036216A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0516132A (pt) | 2004-10-07 | 2007-12-04 | Vitae Pharmaceuticals Inc | compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica |
| TWI411607B (zh) * | 2005-11-14 | 2013-10-11 | Vitae Pharmaceuticals Inc | 天門冬胺酸蛋白酶抑制劑 |
| CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
| WO2009096996A1 (en) * | 2007-06-20 | 2009-08-06 | Smithkline Beecham Corporation | Renin inhibitors |
| US20100160424A1 (en) * | 2007-06-20 | 2010-06-24 | Baldwin John J | Renin inhibitors |
| US8889714B2 (en) | 2008-05-05 | 2014-11-18 | Actelion Pharmaceuticals Ltd. | 3,4-substituted piperidine derivatives as renin inhibitors |
| WO2009154766A1 (en) * | 2008-06-20 | 2009-12-23 | Vitae Pharmaceuticals, Inc. | Renin inhibitors and method of use thereof |
| CN102088850A (zh) * | 2008-06-26 | 2011-06-08 | 生命医药公司 | 甲基2-((r)-(3-氯苯基)((r)-1-((s)-2-(甲氨基)-3((r)-四氢-2h-吡喃-3-基)丙基氨甲酰基)哌啶-3-基)甲氧基)氨基甲酸乙酯的盐 |
| US20100010228A1 (en) * | 2008-06-26 | 2010-01-14 | Vitae Pharmaceuticals, Inc. | Process for the asymmetric reduction of 3-benzoylpiperidines |
| AR077692A1 (es) * | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
| US20120164120A1 (en) * | 2010-12-23 | 2012-06-28 | Food Industry Research And Development Institute | Novel monascuspurpurones, preparation process thereof, and uses of the monascuspurpurones |
| JP7290631B2 (ja) | 2017-10-04 | 2023-06-13 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としてのヘテロ環式化合物の誘導体 |
| ES2929476T3 (es) | 2018-03-12 | 2022-11-29 | Bayer Ag | Derivados heterocíclicos bicíclicos condensados como plaguicidas |
| BR112020020081A2 (pt) | 2018-04-20 | 2021-01-05 | Bayer Aktiengesellschaft | Derivados de heterocicleno como agentes de controle de pragas |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3017618A (en) * | 1960-04-25 | 1962-01-16 | Eastman Kodak Co | Device for removing and detecting foreign matter from a surface |
| US4908372A (en) * | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
| DE4018070A1 (de) * | 1990-06-06 | 1991-12-12 | Bayer Ag | Morpholinoharnstoff-derivate |
| EP0561973A1 (en) * | 1990-12-14 | 1993-09-29 | Merrell Dow Pharmaceuticals Inc. | Antiallergic compounds |
| DE69330823T2 (de) * | 1992-02-13 | 2002-05-02 | Merrell Pharmaceuticals Inc., Cincinnati | Thiacyclische piperidinylderivate |
| US6162927A (en) * | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| US6946481B1 (en) * | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US5767144A (en) * | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| GB9826540D0 (en) * | 1998-12-02 | 1999-01-27 | Darwin Discovery Ltd | Process |
| US6900329B2 (en) * | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| AR039555A1 (es) * | 2001-11-08 | 2005-02-23 | Upjohn Co | Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano |
| US7557137B2 (en) * | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
| US20070093492A1 (en) * | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
| BRPI0516132A (pt) * | 2004-10-07 | 2007-12-04 | Vitae Pharmaceuticals Inc | compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica |
| TWI411607B (zh) * | 2005-11-14 | 2013-10-11 | Vitae Pharmaceuticals Inc | 天門冬胺酸蛋白酶抑制劑 |
| WO2007117557A2 (en) * | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| CL2007002689A1 (es) * | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
| WO2009096996A1 (en) * | 2007-06-20 | 2009-08-06 | Smithkline Beecham Corporation | Renin inhibitors |
| US20100160424A1 (en) * | 2007-06-20 | 2010-06-24 | Baldwin John J | Renin inhibitors |
| US7773441B2 (en) * | 2008-06-18 | 2010-08-10 | Micron Technology, Inc. | Memory malfunction prediction system and method |
-
2007
- 2007-09-17 JP JP2009528319A patent/JP2010503682A/ja not_active Withdrawn
- 2007-09-17 EP EP07838310A patent/EP2081927B1/en active Active
- 2007-09-17 AT AT07838310T patent/ATE520690T1/de not_active IP Right Cessation
- 2007-09-17 WO PCT/US2007/020086 patent/WO2008036216A1/en not_active Ceased
- 2007-09-17 US US12/311,020 patent/US20090318501A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7166599B2 (en) | Trisubstituted pyrimidines | |
| US8188125B2 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
| KR100967070B1 (ko) | 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제 | |
| US20210363148A1 (en) | Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity | |
| IL292877B2 (en) | Angiotensinogen IRNA preparations and methods of using them | |
| US5401738A (en) | Benzimidazole compounds | |
| TW200825058A (en) | Cysteine protease inhibitors | |
| HUP0103752A2 (hu) | N,N-diszubsztituált amidszármazékok, valamint ezeket tartalmazó gyógyászati készítmények az integrinek receptorokhoz való kötődésének gátlására | |
| JPWO2005047286A1 (ja) | スピロ複素環化合物 | |
| JP2008513516A5 (enExample) | ||
| EA009743B1 (ru) | Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 | |
| CA3086662C (en) | Nitrogen-containing 6-membered cyclic compound | |
| JP2008513498A5 (enExample) | ||
| RU2009110442A (ru) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой | |
| JPWO2003030937A1 (ja) | ミトコンドリアルベンゾジアゼピン受容体アンタゴニストからなるストレス疾患の治療剤 | |
| HRP20130144T4 (hr) | Inhibitori renina | |
| JP2010503682A (ja) | レニン阻害剤としてのピペリジン誘導体 | |
| JP2009515893A5 (enExample) | ||
| CN100349893C (zh) | 用作磷酸二酯酶抑制剂的取代2,4－二氢－吡咯并[3,4－b]喹啉－9－酮衍生物 | |
| US7812026B2 (en) | Imidazole derivatives having a positive allosteric GABAB receptor modulator effect and methods of use | |
| JPH0748360A (ja) | ビフェニルテトラゾール誘導体 | |
| RU2374228C2 (ru) | Производные 4-фенилпиперидина в качестве ингибиторов ренина | |
| JP2010522168A (ja) | 鉱質コルチコイドレセプターモジュレータ | |
| JP6151775B2 (ja) | 新規のテトラゾール誘導体及びカリウムチャネルモジュレータとしてのその使用 | |
| RU2007132438A (ru) | Циклопропил-(2,3-диметилбензил)амид 7-{4-[2-(2,6-дихлор-4-метилфенокси)этокси]фенил}-3,9-диазабицикло[3.3.1]нон-6-ен-6-карбоновой кислоты в качестве ингибиторов ренина для лечения артериальной гипертензии |